Results 21 to 30 of about 1,639,464 (252)
Oral malignant melanoma
Journal of Indian Academy of Oral Medicine and Radiology, 2018 Primary malignant melanoma of the oral cavity is a rare neoplasm. In this article, we report the case of a 55-year-old woman with primary malignant melanoma of the maxillary gingiva.Y C Chaitanya, P Vinil Chaitanya, M Venkat Reddy, B Bhavya +3 moredoaj +1 more sourceMucosal Melanoma In Situ of the Oral Cavity: A Case Report and Systematic Review of the Literature [PDF]
, 2022 Objective:Malignant mucosal melanomas of the head and neck comprise a very small portion of all melanomas, particularly in the oral cavity. These lesions are associated with high rates of local recurrence, distant metastasis, and a very poor 5-year ...Jim Howell, Neville, Brad W., Terry A. Day, Nicolas S. Poupore, W. Nicholas Jungbauer, Brad W. Neville, Jungbauer, W. Nicholas, Day, Terry A., Polly Jasper, Poupore, Nicolas S., Nguyen, Shaun A., Howell, Jim, Shaun A. Nguyen, Jasper, Polly +13 morecore +1 more sourceTNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation
Hepatology, EarlyView., 2022 Abstract Background and Aims
Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara +16 morewiley +1 more sourceAssociation of MC1R Variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study [PDF]
, 2010 <p><b>Background</b> Carrying the cyclin-dependent kinase inhibitor 2A (CDKN2A) germline mutations is associated with a high risk for melanoma. Penetrance of CDKN2A mutations is modified by pigmentation characteristics, nevus phenotypes,Pastorino, L., Melanoma Genetics Consortium, Goldstein, A M, Taylor JC, Ming M, Taylor Y, Martin NG, PUIG S, Rull R, Gliori S, Holland EA., Gonzalez M, Calista, D, Mackie, R.M., Lindén D, N. K. Hayward, Randerson-Moor, J, Palou J, Vilalta A, Ming, M. E., V. Höiom, Belle, P. van, Conill C, Gillanders, E, Avril, M.F., Vidal-Sicart S, Carrera, C., Bishop, J.A.N., Lang, J. M., Bishop, D. T., Mohamdi, H., GRUIS N, Bressac-de Paillerets, B, BIANCHI-SCARRÀ G, Gruis NA, P. A. Kanetsky, Bressac-de Paillerets, B., Malvehy J, N. Gruis, Whiteman DC, CARRERA C, Hayward, N. K., Tucker, M.A., G. J. Mann, van der Velden, P, Badenas C, R. M. Mackie, Stark, M., Nasti S, Marti-Laborda R, GenoMEL, Harbst K, V. Chaudru, RANDERSON-MOOR J, B. Bressac-de Paillerets, C. Ingvar, ELDER DE, PASTORINO L, J. Randerson-Moor, Tsao, H, Mohamdi, H, Landi G, Cuellar F, HAYWARD NK, AVRIL MF, Brassac-de Paillerets, B., Minghetti P, van Belle, P., Carrera, C, C. J. Njauw, Kanetsky P, GenoMEL,, E. Gillanders, A. M. Goldstein, Calista, D., Hayward, N K, Gargiulo S, W. BRUNO, Kanetsky, P.A., Arguís P, Bianchi-Scarra, G., L. Pastorino, D. E. Elder, Bertazzi PA, BERGMAN W, Chaudru, V, Mackie, R M, HÖIOM V, Battistuzzi L, Duffy DL, Origone P, Elder, D. E., Holland, E.A., HANSSON J, MacGregor S, MANN GJ, TUCKER MA, Mack T, Lang, J.M., F. Demenais, X. R. Yang, Ancero A, de Lichy M, Newton Bishop, J. A., Bianhi-Scarrà G, Landi, MT, Leake S, Mann, G J, Landi, M.T., VAN BELLE P, Stark, M, Hayward, N.K., van Mourik L, Yang, X.R., Parossian S, Demenais, F, Nielsen K, Elder, D.E., Tsao, H., Arcangeli F, Montgomery GW, MOHAMDI H, CHAUDRU V, J. Palmer, Mackie, R., M. E. Ming, Demenais, F., AZIZI E, Ming, M E, M. T. Landi, Azizi, E., Holland, E A, Randerson-Moor, J., Alós L, Gruis, N, Olsson, Håkan, J. M. Lang, van Nieuwpport FA, Castel T, LANDI MT, LANG JM, M. F. Avril, Haynes S, Kanetsky, P. A., Queirolo P, Karpavicius B, BISHOP DT, Palmer, J., M. Harland, Hogg, D., J. Hansson, CALISTA D, VAN DER VELDEN P, van der Velden, P., Yang, X R, Chaudru, V., Bergman, W., van Belle, P, Chan M, Höiom, V, BRUNO W, Kanetsky, P A, PALMER J, NJAUW CJ, Lang, J., H. Tsao, Sánchez M, G. Bianchi-Scarrà, Vilella R, NEWTON BISHOP JA, Avril, M F, Maubec E, Goldstein, A.M., P. van der Velden, J. A. Newton Bishop, KANETSKY PA, Mila M, Hoiom, V., Melanoma Genetics Consortium: Demenais F, H. Olsson, BRESSAC-DE PAILLERETS B, Harland, M, Tuominen R, E. A. Holland, Affleck P, Whittaker L, Loo JC, Mackie, R. M., Tesema L, Njauw, C. J., Iles MM, Borg Å, Holland, E. A., Ingvar, Christian, MACKIE RM, Hansson, J., HOLLAND EA, GHIORZO P, Butille JA, Cervera R, Ogbah Z, Azizi, E, Bishop, D.T., C. Carrera, Velden, P. van der, Landi, M. T., Campo A, Ming, M.E., Newton Bishop, J A, Jeannin P, Lang, J M, Bishop, D T, MING ME, Njauw, C J, E. Azizi, HARLAND M, Lang J, M. A. Tucker, Elder D, Gabriel D, Gruis, N., Gillanders, E., W. Bergman, Lesueur F, Capirossi D, DEMENAIS F, STARK M, Mackie R, Ingvar, C., GILLANDERS E, Njauw, C.J., P. van Belle, Barrett JH, GOLDSTEIN AM, M. Stark, Hogg, D, Iglesias P, Puig, S., D. Hogg, Elder, D E, INGVAR C, Kukalizch K, Mann, G.J., Olsson, H., Bergman, W, Pastorino, L, Mann, G. J., S. Puig, Schmid H, Tucker, M A, D. Calista, Mitra N, TSAO H, YANG XR, Kefford RF, P. GHIORZO, Njauw CN, Avril, M. F., Jönsson G, Harrison J, HOGG D, Ruffin A, Aguilera P, D. T. Bishop, Corda E, OLSSON H, Puig, S, Hansson, J, Palmer, J, Bianchi-Scarrà, G, H. Mohamdi, Måsbäck A, Newton Bishop, J.A., Harland, M., Goldstein, A. M., Olsson, Håkan,, Bishop, DT, Ingvar, Christian,, Hayward, NK, Bishop, JAN, Lund University., Goldstein, AM, Kanetsky, PA, Elder, DE +283 morecore +1 more sourceProspects for non-immunological molecular therapeutics in melanoma [PDF]
, 2010 In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,Tryfonopoulos, Dimitrios, Eustace, Alexander J., Mahgoub, Thamir, O\u27Donovan, Norma, Crown, John, O'Donovan, Norma +5 morecore +2 more sourcesMalignant melanoma: A rare case report
Journal of Indian Academy of Oral Medicine and Radiology, 2016 Malignant melanoma in the oral cavity accounts for only 0.2–8% of all malignant melanomas and it has a much poorer prognosis than its counterpart on the skin.Mallika Kishore, Sunil R Panat, Abhinav Kishore, Abhijeet Alok +3 moredoaj +1 more sourceOral Malignant Melanoma: The Amsterdam Experience
, 2007 Purpose: The purpose of this study was to evaluate the clinical, pathological, and therapeutic experience of a group of patients with primary oral malignant melanoma (OMM) in Amsterdam, The Netherlands. Patients and Methods: Fourteen patients (5 males, 9 van der Waal, Isaäc, Leemans, C. René, Meleti, Marco, Mooi, Wolter J. +3 morecore +1 more source